Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-α2b

Bone Marrow Transplantation

Volumn 19, Issue 11, 1997, Pages 1151-1153

  Singhal, S ^a,b   Powles, R ^a   Treleaven, J ^a   Mehta, J ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Acute myeloid leukemia; Graft versus host disease; Graft versus leukemia; Immunotherapy; Interferon; Interleukin 2

Indexed keywords

CYCLOSPORIN; CYTOKINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHORIOCARCINOMA; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; PRIORITY JOURNAL; RELAPSE; REMISSION; SCLERODERMA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030919485     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700793     Document Type: Article

References (12)

1. Komori T, Sugiyama H, Ogawa H et al. Treatment of a patient in a relapse after bone marrow transplantation for acute lymphoblastic leukemia with the systemic administration of allogeneic lymphokine-activated killer cells and recombinant interleukin-2. Eur J Haematol 1989; 43: 184-185.
2. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993; 11: 109-111.
3. Mehta J, Powles R, Singhal S et al. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 133-137.
4. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
5. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
6. Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma 1993; 10: 427-432.
7. Meyers JD, Flournoy N, Sanders JE et al. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 1987; 107: 809-816.
8. Pavord S, Sivakumaran M, Durrant S, Chapman C. The role of alpha interferon in the pathogenesis of GVHD. Bone Marrow Transplant 1992; 10: 477.
9. Shaffer L, Giralt S, Champlin R, Chan KW. Treatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2. Bone Marrow Transplant 1995; 15: 317-319.
10. Balkwill FR. Peptide regulatory factors: interferons. Lancet 1989; 1: 1060-1063.
11. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood 1993; 81: 1414-1423.
12. Mehta J, Powles R, Treleaven J et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997; 19: 709-719.